Link Therapeutics specializes in developing therapeutic methods for targeting autoantibodies and identifying pathogenic autoantibodies.
Link Therapeutics has raised $5.7M in total funding. The most recent round was Series B. The last funding was announced in July 2025.
Link Therapeutics's investors include Mitsubishi UFJ Capital, SMBC Venture Capital, Kyoto University Innovation Capital, ITOCHU Technology Ventures, Kobe University Capital.
Link Therapeutics is headquartered in Kyoto, Japan.
Link Therapeutics specializes in developing therapeutic methods for targeting autoantibodies and identifying pathogenic autoantibodies.
Link Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Link Therapeutics — Funding & Investors." VCBacked, July 18, 2025, https://www.vcbacked.co/company/link-therapeutics. Accessed September 30, 2026.
VCBacked. (2025). Link Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/link-therapeutics
{{cite web |title=Link Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/link-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated